Author's response to reviews

Title: Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy

Authors:

Mark A Miller (mmiller@lab.jgh.mcgill.ca)
Thomas Louie (thomas.louie@calgaryhealthregion.ca)
Kathleen Mullane (kmullane@medicinebsd.uchicago.edu)
Karl Weiss (weisscan@aol.com)
Arnold Lentnek (arnold.lentnek@earthlink.net)
Yoav Golan (ygolan@tuftsmedicalcenter.org)
Yin Kean (ykean@optimerpharma.com)
Pam Sears (psears@optimerpharma.com)

Version: 3 Date: 12 January 2013

Author's response to reviews: see over
Enclosed please find the revised re-submitted manuscript entitled “Derivation and validation of a simple clinical bedside score (ATLAS) for *Clostridium difficile* infection which predicts response to therapy” for consideration of publication in BMC Infectious Disease.

This revision, as requested, now includes:

- the fact that all study subjects gave informed consent allowing the analysis which was performed (stated in the methods section on lines 58-59)
- an “authors’ contributions section” on lines 187-191
- a “competing interest section” on lines 193-201

We would like to thank you once again for your kind consideration of this manuscript for publication in BMC Infectious Disease. This analysis takes advantage of one of the world’s largest database of CDI patients to create a simple bedside scoring system which can be used to predict response to CDI therapy. We hope that the ATLAS score could become an invaluable tool for stratifying CDI patients in order to choose various CDI therapies, for prognosticating treatment success, and for categorizing patients who enter CDI therapeutic research trials.

Most sincerely,

Mark Miller, MD, FRCPC
Division of Infectious Diseases
Jewish General Hospital and McGill University
3755 Cote-Ste-Catherine
Montreal, Quebec, Canada H3T 1E2

Tel: 514-340-8294
Fax: 514-340-7546
Email: mmiller@lab.jgh.mcgill.ca